top of page

TRANSVAC October Newsletter is out!

Updated: Jul 29, 2020

TRANSVAC Training Modules 📖

OPEN CALL | Submit your application for TRANSVAC Courses now

In brief: This course is designed to critically discuss the design of animal studies: choice of animal models, presentation of less frequently used animal species, animal numbers and the extrapolation of results to humans.

Where? Wageningen University, The Netherlands

When? 12-13 March 2020

In brief: Cytometry by time of flight (CyTOF) or mass cytometry allows the simultaneous detection of multiple phenotypic markers at the single cell level. You can learn a theory and practice of mass-cytometry applied to assessing the immune response in human and animal models.

Where? CEA, France

When? 4-5 March 2020

To be introduced to multimodal in vivo imaging from the basic principles including basics in biophysics, methodologies for in vivo imaging, to image analysis and biological interpretation of the results.

Where? CEA, France

When? 2-4 March 2020

⏳ Apply here until November 15th, 2019

TRANSVAC Vaccine Development Services 🧪

OPEN CALL | Submit your application for TNA services now

TRANSVAC2 project offers high-quality technical services to support the development of prophylactic and therapeutic vaccines for both human and animal use.

- These services are not restricted to any disease in particular.

- Services will be offered free of charge, with few exceptions!

- Academic and non-academic research groups, SMEs and industries can apply but only to service infrastructures outside their own country.

⏳ Apply here until December 15th, 2019

📣 New partnership with ERINHA-Advance allows TRANSVAC users to apply with projects studying highly infectious pathogens.

The first TNA Call to ERINHA’s full catalogue of services, including access to cutting‑edge high‑containment facilities was also launched on October 15th, 2019.

The following pathogens are prioritized within this call: Ebola virus, Marburg virus, Lassa virus, Crimean‑Congo Hemorrhagic Fever virus and Nipah virus.

Applicants with interest in highly pathogenic agents and vaccine development are encouraged to apply to both calls. More info >>>


The Vaccine Development Department at SSI is responsible for a wide range of tasks including development of manufacturing processes for new biological products and adjuvants; formulation and analysis development, and manufacturing of products for clinical trials. For more details visit the Vaccine Development Department and Vaccine Adjuvant research webpages.


bottom of page